Mylan's Latest Focalin ANDA Brings Novartis IP Suit

Law360, New York (December 14, 2012, 3:53 PM EST) -- Celgene Corp. and Novartis Pharma AG has slapped Mylan Pharmaceuticals Inc. with a lawsuit in New Jersey federal court alleging the generic and specialty pharmaceutical company violated six of their patents when it applied to produce new versions of the attention deficit hyperactivity disorder drug Focalin XR.

The suit, filed Dec. 7, is the latest in the patent holders' attempt to block Mylan from producing its own versions of the drug, known generically as dexmethlyphenidate hydrochloride. In January, the companies reached a confidential settlement to end a dispute...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.